Summary
Pharmaceuticals in Scandinavia industry profile provides top-line qualitative and quantitative summary information including: market size (value 2019-24, and forecast to 2029). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Highlights
- The pharmaceutical market includes sales of both prescriptions and over-the-counter (OTC) drugs. The market scope does not cover consumer healthcare and animal health products.
- The Scandinavian pharmaceuticals market recorded revenues of $17.5 billion in 2024, representing a compound annual growth rate (CAGR) of 3.5% between 2019 and 2024.
- The central nervous system drugs segment accounted for the market's largest proportion in 2024, with total revenues of $2.3 billion, equivalent to 12.9% of the market's overall value.
- Sweden dominated the Scandinavian pharmaceuticals market in 2024, accounting for the largest share of 42.0%, followed by Norway, capturing a share of 30.0%.
Scope
- Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the pharmaceuticals market in Scandinavia
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in Scandinavia
- Leading company profiles reveal details of key pharmaceuticals market players’ global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the Scandinavia pharmaceuticals market with five year forecasts
Reasons to Buy
- What was the size of the Scandinavia pharmaceuticals market by value in 2024?
- What will be the size of the Scandinavia pharmaceuticals market in 2029?
- What factors are affecting the strength of competition in the Scandinavia pharmaceuticals market?
- How has the market performed over the last five years?
- What are the main segments that make up Scandinavia's pharmaceuticals market?
'
Table of Contents
1 Executive Summary
1.1. Market value
1.2. Market value forecast
1.3. Category segmentation
1.4. Geography segmentation
1.5. Market rivalry
1.6. Competitive landscape
2 Market Overview
2.1. Market definition
2.2. Market analysis
3 Market Data
3.1. Market value
4 Market Segmentation
4.1. Category segmentation
4.2. Geography segmentation
5 Market Outlook
5.1. Market value forecast
6 Five Forces Analysis
6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry
7 Competitive Landscape
7.1. Who are the leading players?
7.2. What are the strategies of the leading players?
7.3. What are the most recent market developments?
8 Company Profiles
8.1. F. Hoffmann-La Roche Ltd
8.2. H. Lundbeck AS
8.3. Novo Nordisk AS
9 Macroeconomic Indicators
9.1. Country data
10 Appendix
10.1. Methodology
10.2. Industry associations
10.3. Related MarketLine research
10.4. About MarketLine
List of Tables
Table 1: Scandinavia pharmaceuticals market value: $ million, 2019-24
Table 2: Scandinavia pharmaceuticals market category segmentation: % share, by value, 2019-24
Table 3: Scandinavia pharmaceuticals market category segmentation: $ million, 2019-24
Table 4: Scandinavia pharmaceuticals market geography segmentation: $ million, 2024
Table 5: Scandinavia pharmaceuticals market value forecast: $ million, 2024-29
Table 6: F. Hoffmann-La Roche Ltd: Key Facts
Table 7: F. Hoffmann-La Roche Ltd: Key Employees
Table 8: H. Lundbeck AS: Key Facts
Table 9: H. Lundbeck AS: Annual Financial Ratios
Table 10: H. Lundbeck AS: Key Employees
Table 11: Novo Nordisk AS: Key Facts
Table 12: Novo Nordisk AS: Annual Financial Ratios
Table 13: Novo Nordisk AS: Key Employees
Table 14: Scandinavia Exchange Rate, 2019-24
List of Figures
Figure 1: Scandinavia pharmaceuticals market value: $ million, 2019-24
Figure 2: Scandinavia pharmaceuticals market category segmentation: $ million, 2019-24
Figure 3: Scandinavia pharmaceuticals market geography segmentation: % share, by value, 2024
Figure 4: Scandinavia pharmaceuticals market value forecast: $ million, 2024-29
Figure 5: Forces driving competition in the pharmaceuticals market in Scandinavia, 2024
Figure 6: Drivers of buyer power in the pharmaceuticals market in Scandinavia, 2024
Figure 7: Drivers of supplier power in the pharmaceuticals market in Scandinavia, 2024
Figure 8: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Scandinavia, 2024
Figure 9: Factors influencing the threat of substitutes in the pharmaceuticals market in Scandinavia, 2024
Figure 10: Drivers of degree of rivalry in the pharmaceuticals market in Scandinavia, 2024
